Both in Pharmaceuticals
Arvinas vs Gyre Therapeutics
Over the past year ARVN returned −28.2% and GYRE returned −38.9%; their daily moves had a correlation of 0.18.
ARVN −28.2% GYRE −38.9%Growth of $1, one year, split-adjusted
| Metric | ARVN | GYRE |
|---|---|---|
| Price | $6.98 | $4.50 |
| Market cap | $456.4M | $477.2M |
| Today | −7.18% | −4.86% |
| 1 month | −6.4% | −38.8% |
| 6 months | −34.2% | −42.2% |
| Year to date | −41.1% | −36.3% |
| 1 year | −31.2% | −41.9% |
| Revenue growth (YoY) | +1014.7% | −2.1% |
| Gross margin | 96.4% | 92.4% |
| Net margin | 67.8% | −40.1% |
| P/E (TTM) | 49.1× | — |
| Price / sales | 1.4× | 4.0× |
| Net cash | $567.6M | $74.8M |
| Dividend yield | — | — |
| Volatility (60d) | 49.2% | 88.0% |
| Short % of float | 10.2% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).